Celldex Therapeutics CLDX Proceeds from issuance of common stock relating to employee stock plans
Proceeds from issuance of common stock relating to employee stock plans at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's proceeds from issuance of common stock relating to employee stock plans.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's proceeds from issuance of common stock relating to employee stock plans?
- Celldex Therapeutics (CLDX) reported proceeds from issuance of common stock relating to employee stock plans of $327K in Q1 2026.
- How has Celldex Therapeutics's proceeds from issuance of common stock relating to employee stock plans changed year-over-year?
- Celldex Therapeutics's proceeds from issuance of common stock relating to employee stock plans increased by 61.9% year-over-year, from $202K to $327K.
- What is the long-term trend for Celldex Therapeutics's proceeds from issuance of common stock relating to employee stock plans?
- Over 4 years (2021 to 2025), Celldex Therapeutics's proceeds from issuance of common stock relating to employee stock plans has grown at a -1.2% compound annual growth rate (CAGR), from $2.5M to $2.39M.